Officials are assessing whether hydromethylthionine mesylate (HMTM) shows sufficient promise to be given the green light for ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...

Frankl believed that life can be made meaningful in a three-fold way: through what we give (in terms of creative work), from ...

Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease.

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

The Alzheimer's Society says it is preparing for its busiest time of the year after families begin to notice signs of the ...

Women with early bilateral oophorectomy (BO) are at high risk of Alzheimer disease (AD) compared to women with spontaneous ...

The presence of CVD may increase the risk of developing dementia among older patients with RA, though CVD was not found to ...